Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biogen Inc. is conducting a Phase 3 long-term extension study titled A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE), focusing on the occurrence of adverse events and the drug’s impact on disease symptoms and quality of life.
The study tests litifilimab, a drug administered via subcutaneous injections, intended to manage symptoms of SLE by reducing disease activity and preventing organ damage. Participants continue their standard care medications alongside the trial drug.
This interventional study employs a randomized, parallel assignment model with quadruple masking to ensure unbiased results. Its primary purpose is treatment, aiming to provide insights into the drug’s long-term safety and effectiveness.
The study began on June 10, 2022, with an estimated completion date of June 30, 2025. These dates are crucial for tracking the study’s progress and anticipating potential market impacts.
The update on this study could influence Biogen’s stock performance positively, as successful results may enhance investor confidence and position Biogen favorably against competitors in the SLE treatment market. Investors should monitor this study’s developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.